Publications

Nature medicine

Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein.

01-11-1997

Journal of chromatography. B, Biomedical sciences and applications

Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction.

15-08-1997

Journal of pharmaceutical sciences

The functional role of P-glycoprotein in the blood-brain barrier.

01-08-1997

Seminars in oncology

Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.

01-08-1997

Annals of oncology : official journal of the European Society for Medical Oncology

Successful intraperitoneal suramin treatment of peritoneal mesothelioma.

01-08-1997

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

01-05-1997

Annals of oncology : official journal of the European Society for Medical Oncology

Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer.

01-04-1997

Proceedings of the National Academy of Sciences of the United States of America

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

04-03-1997

Cancer treatment reviews

Alternative formulations of paclitaxel.

01-03-1997

PDA journal of pharmaceutical science and technology

Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur.

01-03-1997

Cancer treatment reviews

Growth factors in human ovarian cancer.

01-03-1997

Seminars in oncology

Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.

01-02-1997

Cancer chemotherapy and pharmacology

The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue.

01-01-1997

British journal of cancer

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

01-01-1997

British journal of cancer

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

01-01-1997

Cancer chemotherapy and pharmacology

Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan.

01-01-1997

Journal of pharmaceutical and biomedical analysis

The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma.

01-11-1996

British journal of pharmacology

Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

01-11-1996

Journal of pharmaceutical sciences

Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244).

01-11-1996

Pharmacy world & science : PWS

Etoposide phosphate, the water soluble prodrug of etoposide.

01-10-1996

Clinical pharmacokinetics

Clinical pharmacokinetics of topotecan.

01-08-1996

European journal of cancer (Oxford, England : 1990)

The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis.

01-08-1996

Journal of the National Cancer Institute

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

17-07-1996

Journal of chromatography. B, Biomedical applications

Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.

07-06-1996

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.

01-06-1996

Drug metabolism and disposition: the biological fate of chemicals

Isolation, purification and biological activity of major docetaxel metabolites from human feces.

01-06-1996

Cancer research

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.

01-05-1996

British journal of cancer

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.

01-05-1996

British journal of cancer

Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.

01-04-1996

Cancer chemotherapy and pharmacology

Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.

01-01-1996

Cancer chemotherapy and pharmacology

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.

01-01-1996

Investigational new drugs

Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9.

01-01-1996

Anti-cancer drugs

Tissue distribution, metabolism and excretion of paclitaxel in mice.

01-01-1996

Cancer chemotherapy and pharmacology

Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.

01-01-1996

Journal of chromatography. B, Biomedical applications

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.

15-12-1995

Journal of pharmaceutical and biomedical analysis

High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.

01-12-1995

PDA journal of pharmaceutical science and technology

The influence of formulation excipients on the stability of the novel antitumor agent carzelesin (U-80,244).

01-11-1995

Proceedings of the National Academy of Sciences of the United States of America

Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.

15-08-1995

British journal of cancer

CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.

01-07-1995

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

01-07-1995

Journal of chromatography. B, Biomedical applications

High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.

09-06-1995

Cancer treatment reviews

High-dose chemotherapy regimens for solid tumors.

01-03-1995

Journal of cancer research and clinical oncology

The use of the Calvert formula to determine the optimal carboplatin dosage.

01-01-1995

Cancer chemotherapy and pharmacology

Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.

01-01-1995

British journal of cancer

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.

01-07-1994

Cell

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

20-05-1994

Annals of oncology : official journal of the European Society for Medical Oncology

Intraperitoneal-administered carboplatin in patients with ovarian cancer; influence of a dwell-time on toxicity and response.

01-02-1994

Journal of chromatography

Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma.

14-01-1994

Cancer chemotherapy and pharmacology

Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.

01-01-1994

Cancer chemotherapy and pharmacology

Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9.

01-01-1994

Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein.

Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction.

The functional role of P-glycoprotein in the blood-brain barrier.

Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.

Successful intraperitoneal suramin treatment of peritoneal mesothelioma.

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer.

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

Alternative formulations of paclitaxel.

Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur.

Growth factors in human ovarian cancer.

Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.

The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue.

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan.

The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma.

Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244).

Etoposide phosphate, the water soluble prodrug of etoposide.

Clinical pharmacokinetics of topotecan.

The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis.

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.

Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.

Isolation, purification and biological activity of major docetaxel metabolites from human feces.

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.

Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.

Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.

Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9.

Tissue distribution, metabolism and excretion of paclitaxel in mice.

Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.

High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.

The influence of formulation excipients on the stability of the novel antitumor agent carzelesin (U-80,244).

Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.

CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.

High-dose chemotherapy regimens for solid tumors.

The use of the Calvert formula to determine the optimal carboplatin dosage.

Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Intraperitoneal-administered carboplatin in patients with ovarian cancer; influence of a dwell-time on toxicity and response.

Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma.

Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.

Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9.

This site uses cookies